The scientific rationale behind the development of Souvenaid is based on the ability of specific nutrients to support neuronal membrane and synapse formation. Patients with Alzheimer’s disease have specific nutritional needs and it has been hypothesised that providing the right combination of nutrients may provide clinically relevant benefits in this population. Over 10 years of research have contributed to the development of Souvenaid – preclinical work conducted by scientists at the Massachusetts Institute of Technology (MIT) formed the foundation for our clinical trial programme